In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia

Neuropsychopharmacology

Volumn 23, Issue 1, 2000, Pages 56-68

  Raedler, Thomas J ^a   Knable, Michael B ^a,b   Jones, Douglas W ^a   Lafargue, Todd ^a   Urbina, Richard A ^a   Egan, Michael F ^a   Pickar, David ^a   Weinberger, Daniel R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b Stanley Medical Research Institute   (United States)

Author keywords

Antipsychotic; IQNB; Muscarinic receptor; Olanzapine; Schizophrenia; SPECT

Indexed keywords

IODINE 123; MUSCARINIC M2 RECEPTOR; MUSCARINIC RECEPTOR; OLANZAPINE; QUINUCLIDINYL BENZILATE;

ADULT; ANTICHOLINERGIC EFFECT; ARTICLE; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; IN VIVO STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PONS; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TACHYCARDIA; THALAMUS;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; RECEPTORS, MUSCARINIC; SCHIZOPHRENIA;

EID: 0034084299     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00162-1     Document Type: Article

References (58)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association Press.
2. Aquilonius S.-M., Eckernas S.-A. A colour atlas of the human brain. 1980;Raven Press, New York.
3. Aravagiri M., Ames D., Wirshing W.C., Marder S.R. Plasma level monitoring of olanzapine in patients with schizophrenia. determination by high-performance liquid chromatography with electrochemical detection Ther Drug Monit. 19:1996;307-313. see also "Zyprexa (Olanzapine)" drug monograph PV2965AMP, Eli Lilly and Co. (1998).
4. Beasley C.M., Hamilton S.H., Crawford A.M., Dellva M.A., Tollefson G.D., Tran P.V., Blin O., Beuzen J.N. Olanzapine versus haloperidol. acute phase results of the international double-blind olanzapine trial Eur Neuropsychopharmacol. 7:1997;125-137.
5. Beasley C.M., Sanger T., Satterlee W., Tollefson G., Tran P., Hamilton S. Olanzapine versus placebo. results of a double-blind, fixed-dosed olanzapine trial Psychopharmacology (Berl). 124:1996;159-167. a.
6. Beasley C.M., Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S. Olanzapine versus placebo and haloperidol. acute phase results of the North American double-blind olanzapine trial Neuropsychopharmacology. 14:1996;111-123. b.
7. Bolden C., Cusack B., Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther. 260:1992;576-580.
8. Bonner T.I., Buckley N.J., Young A.C., Brann M.R. Identification of a family of muscarinic acetylcholine receptor genes. Science. 237:1987;527-532.
9. Bonner T.I., Young A.C., Brann M.R., Buckley N.J. Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron. 1:1988;403-410.
10. 125I]-4IQNB binding to the muscarinic acetylcholine receptor in relationship to the regional subtype composition. Receptor. 5:1995;207-218.
11. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96. a.
12. Bymaster F.P., Hemrick-Luecke S.K., Perry K.W., Fuller R.W. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl). 124:1996;87-94. b.
13. 1-adrenergic receptors in vitro. Schizophr Res. 37:1999;107-122.
14. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 192:1976;481-483.
15. Dean B., Crook J.M., Opeskin K., Hill C., Keks N., Copolov D.L. The density of muscarinic M(1) receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry. 1:1996;54-58.
16. Duvernoy H.M. The human brain. 1991;three-dimensional sectional anatomy and MRI. Vienna, Springer-Verlag, Surface.
17. Eckelman W.C., Reba R.C., Rzeszotarski W.J. External imaging of cerebral muscarinic acetylcholine receptors. Science. 223:1984;291-292.
18. Eli Lilly and Company (1999): Zyprexa (Olanzapine). In Physicians' Desk Reference, 53rd ed., Montvale, NJ, Medical Economics Company, Inc., pp 1641-1645.
19. Farde L., Nordström A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 49:1992;538-544.
20. 3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain. Synapse. 14:1993;283-296.
21. 2 receptor imaging and neuroleptic response. J Clin Psychiatry. 57(Suppl 11):1996;84-88.
22. Jones D.W., Heinz A., Gorey J.G., Lee K.S., Knable M.B., Urbina R.A., Weinberger D.R. A simple, sensitive and efficient method of directly determining plasma concentrations of free [I-123]β-CIT at extended times by TLC of ultrafiltrates. J Nucl Med (suppl). 38:1997;287P.
23. 2 antagonism and EPS benefits. is there a causal connection? Psychopharmacology. 124:1996;35-39.
24. 2 receptor occupancy of olanzapine in schizophrenia. a PET investigation Am J Psychiatry. 155:1998;921-928.
25. Kay S.R., Opler L.A., Fiszbein A. Positive and Negative Syndrome Scale (PANSS). 1986;Manual. Multi-Health Systems, North Tonawanda NY.
26. Lee K.S., He X.S., Jones D.W., Coppola R., Gorey J.G., Knable M.B., deCosta B.R., Rice K.C., Weinberger D.R. An improved method for rapid and efficient radioiodination of iodine- 123-IQNB. Nucl Med. 37:1996;2021-2024.
27. Levey A.I., Kitt C.A., Simonds W.F., Price D.L., Brann M.R. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci. 11:1991;3218-3226.
28. Li M., Yasuda R.P., Wall S.J., Wellstein A., Wolfe B.B. Distribution of m2 muscarinic receptors in rat brain using antisera selective for m2 receptors. Mol Pharmacol. 40:1991;28-35.
29. McRee R.C., Boulay S.F., Sood V.K., Cohen E.I., Cohen V.I., Gitler M.S., Zeeberg B.R., Gibson R.E., Reba R.C. Autoradiographic evidence that QNB displays in vivo selectivity for the m2 subtype. Neuroimage. 2:1995;55-62.
30. Nordström A.L., Farde L., Wiesel F.A., Forslund K., Pauli S., Halldin C., Uppfeld G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects. a double-blind PET study of schizophrenic patients Biological Psychiatry. 33:1993;227-235.
31. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology. 16:1997;1-7.
32. Overall J.E., Gorham D.E. The Brief Psychiatric Rating Scale. Psychol Rep. 10:1962;799-812.
33. 2 receptor occupancy in patients treated with olanzapine. Psychiatry Res. 90:1999;81-90. a.
34. Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey LG, Lee KS, Weinberger DR (1999b): In vivo observation of a significant reduction of muscarinic acetycholine receptors in schizophrenic patients. (in preparation).
35. Robertson G.S., Fibiger H.C. Effects of olanzapine on regional C-Fos expression in rat forebrain. Neuropsychopharmacology. 14:1996;105-110.
36. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs. in vitro and in vivo receptor binding Psychopharmacology (Berl). 124:1996;57-73.
37. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
38. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 212 [Suppl 44], 11-19:1970.
39. Snyder S., Greenberg D., Yamamura H.I. Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry. 31:1974;58-61.
40. Stockton M.E., Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology. 14:1996;97-104.
41. Sunderland T., Esposito G., Molchan S.E., Coppola R., Jones D.W., Gorey J., Little J.T., Bahro M., Weinberger D.R. Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine. a SPECT study Psychopharmacology (Berl). 121:1995;231-241.
42. Talairach J., Tournoux P. Co-planar stereotaxic atlas of the human brain. 1988;Thieme Medical Publishers, New York.
43. Tandon R., Shipley J.E., Greden J.F., Mann N.A., Eisner W.H., Goodson J. Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms. Schizophrenia Res. 4:1991;23-30.
44. 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology. 141:1999;175-181.
45. Tollefson G.D., Beasley C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders. results of an international collaborative trial Am J Psychiatry. 154:1997;457-465. a.
46. Tollefson G.D., Beasley C.M., Tamura R.N., Tran P.V., Potvin J.H. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 154:1997;1248-1254. b.
47. Tran P.V., Dellva M.A., Tollefson G.D., Beasley C.M., Potvin J.H., Kiesler G.M. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry. 58:1997;205-211.
48. Tune L., Coyle J.T. Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch Gen Psychiatry. 37:1980;293-297.
49. Vilaro M.T., Wiederhold K.-H., Palacios J.M., Mengod G. Mucarinic cholinergic receptors in the rat caudat-putamen and olfactory tubercle belong predominantly to the m4 class. in situ hybridization and receptor autoradiography evidence Neuroscience. 40:1991;159-167.
50. Wall S.J., Yasuda R.P., Hory F., Flagg S., Martin B.M., Ginns E.I., Wolfe B.B. Production of antisera selective for m1 muscarinic receptors using fusion proteins. Distribution of m1 receptors in rat brain Mol Pharmacol. 39:1991;643-649. a.
51. Wall S.J., Yasuda R.P., Li M., Flagg S., Wolfe B.B. Development of an antiserum against m3 muscarinic receptors. Distribution of m3 receptors in rat tissues and clonal cell lines Mol Pharmacol. 40:1991;783-789. b.
52. Watling K.J., Kebabian J.W., Neumeyer J.L. The RBI handbook of receptor classification and signal transduction. 1995;Research Biochemicals International, Natick, MA.
53. Weinberger D.R., Gibson R., Coppola R., Jones D.W., Molchan S., Sunderland T., Berman K.F., Reba R.C. The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dementia. A controlled study with. 123IQNB(and single photon emission computed tomography. Arch Neurol 48):1991;169-176.
54. Wyatt R.J. Practical psychiatric practice. clinical interview forms, rating scales and patient handouts:1993;D.C., American Psychiatric Association Press, Washington.
55. Yamamura H.I., Enna S.J., Kuhar M.J. Neurotransmitter receptor binding. 1985;Raven Press, New York.
56. Yasuda R.P., Ciesla W., Flores L.R., Wall S.J., Li M., Satkus S.A., Weisstein J.S., Spagnola B.V., Wolfe B.B. Development of antisera selective for m4 and m5 muscarinic cholinergic receptors. Distribution of m4 and m5 receptors in rat brain Mol Pharmacol. 43:1993;149-157.
57. Yeomans J.S. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology. 12:1995;3-16.
58. 2A and muscarinic receptors. Psychopharmacology. 141:1999;267-278.